Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.6560
Nov 20 • 3:57 PM ET Dollar change-0.0590 Percentage change(-8.25%)
Aftermarket Close
0.6560
Aftermarket • 7:30 PM ET Dollar change0.0000 Percentage change(0.00%)
Index
-
Market Cap
7.84M
Enterprise Value
-2.77M
Income
-14.67M
Sales
0.00M
Book/sh
0.72
Cash/sh
0.89
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
6
IPO
May 10, 2012
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.91
P/C
0.74
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
4.19
Current Ratio
4.19
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-1.26
EPS next Y
-0.73
EPS next Q
-0.35
EPS this Y
2.76%
EPS next Y
48.23%
EPS next 5Y
-
EPS past 3/5Y
74.81% 62.91%
Sales past 3/5Y
- -
EPS Y/Y TTM
43.66%
Sales Y/Y TTM
-
EPS Q/Q
18.63%
Sales Q/Q
-
Insider Own
15.07%
Insider Trans
7.96%
Inst Own
6.61%
Inst Trans
1.63%
ROA
-128.58%
ROE
-158.97%
ROIC
-170.21%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-19.24%
SMA50
-27.72%
SMA200
-38.69%
Trades
Shs Outstand
11.95M
Shs Float
10.15M
52W High
1.88 -65.11%
52W Low
0.70 -6.57%
Volatility
8.57% 8.15%
ATR (14)
0.06
RSI (14)
22.61
Beta
0.94
Rel Volume
1.32
Avg Volume
110.02K
Volume
145,412
Perf Week
-14.92%
Perf Month
-24.81%
Perf Quarter
-43.93%
Perf Half Y
-39.82%
Perf YTD
-37.52%
Perf Year
-44.87%
Perf 3Y
-92.85%
Perf 5Y
-99.56%
Perf 10Y
-100.00%
Prev Close
0.71
Price
0.66
Change %
-8.25%
Consensus
Strong Buy
Avg. Price Target
$14.00
Implied Upside
+2,034.1%
Analysts1incl. previous ratings
Rating Distribution1 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 05, 2025Resumed
HH.C. Wainwright
Buy$14+2,034.1%
Aug 05, 2020Initiated
HH.C. Wainwright
Buy$4+509.8%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Deming David HDirectorNov 12 '26Buy0.819,0007,32258,800Nov 16 10:30 AM
Deming David HDirectorNov 13 '26Buy0.833,0002,50061,800Nov 16 10:30 AM
Deming David HDirectorNov 10 '26Buy0.846,8005,70944,600Nov 12 09:52 AM
Deming David HDirectorNov 11 '26Buy0.845,2004,35849,800Nov 12 09:52 AM
Plott Ronald ToddDirectorNov 09 '26Buy0.8318,30015,18960,300Nov 10 11:18 AM
Bitterman Robert JChairman, Pres. & CEONov 09 '26Buy0.8225,00020,500789,871Nov 10 11:17 AM
Plott Ronald ToddDirectorSep 29 '26Buy1.045,0005,20042,000Sep 30 04:01 PM
Plott Ronald ToddDirectorSep 28 '26Buy1.035,0005,15037,000Sep 30 04:01 PM
BRADFORD PATRICIA ADirectorSep 24 '26Buy1.016,5006,58364,151Sep 25 04:01 PM
Bitterman Robert JChairman, Pres. & CEOSep 22 '26Buy1.032,0002,058364,871Sep 23 04:01 PM
BRADFORD PATRICIA ADirectorSep 15 '26Buy1.0312,00012,36057,651Sep 16 04:01 PM
Plott Ronald ToddDirectorAug 19 '26Buy1.1415,00017,10015,000Aug 20 08:30 AM
Bitterman Robert JChairman, Pres. & CEOAug 18 '26Buy1.0610,00010,600431,421Aug 19 04:01 PM
Bitterman Robert JChairman, Pres. & CEOJun 26 '26Buy0.9910,0009,900421,421Jun 29 04:02 PM
Bitterman Robert JChairman, Pres. & CEODec 31 '25Buy1.035,0005,150291,421Jan 02 04:05 PM
Bitterman Robert JChairman, Pres. & CEODec 23 '25Buy1.025,0005,100286,421Dec 29 08:10 AM
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the proprietary INTASYL small interfering RNA gene silencing technology designed to make immune cells more effective in killing tumor cells. Its pipelines include PH-762 and PH-894. The company was founded on September 8, 2011 and is headquartered in King of Prussia, PA.
PresidentMr. Robert J. Bitterman
CFOMs. Lisa C. Carson
Senior Vice President of Regulatory & Corporate AffairsDr. Jennifer Phillips Pharm.D.